ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – JNCE, MNTV, UNVR, CVT
March 15, 2023 17:47 ET
|
Monteverde & Associates PC
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NUVA, JNCE, ROCC, TCRR
March 08, 2023 16:00 ET
|
Monteverde & Associates PC
NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Moore Kuehn Encourages PTRS, VBLT, INDT, and JNCE Investors to Contact Law Firm
February 27, 2023 21:28 ET
|
Moore Kuehn
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Jounce Therapeutics Reports First Quarter 2021 Financial Results
May 04, 2021 06:30 ET
|
Jounce Therapeutics, Inc.
- Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab - - Ended the...
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
April 28, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on Tuesday, May 4, 2021
April 27, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
April 12, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
April 10, 2021 08:31 ET
|
Jounce Therapeutics, Inc.
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature- - JTX-8064’s mechanism of...
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
February 23, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
February 18, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...